Systemic Therapy for Metastatic Renal Cell Carcinoma

被引：34

作者：

Kroog, Glenn S. ^{[1
]}

Motzer, Robert J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10065 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2008年 / 35卷 / 04期

关键词：

Renal cell cancer; Kidney cancer; Sunitinib; Sorafenib; Temsirolimus; Targeted therapy;

D O I：

10.1016/j.ucl.2008.07.007

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Renal cell cancer (RCC) is the most common form of cancer of the kidney and accounts for approximately 44,000 cases per year in the United States. Historically, only immunotherapy showed activity in metastatic RCC. The improved survival and quality of life for patients with metastatic RCC over the last several years are direct results of advances made in understanding the development of RCC. Three targeted therapies-sunitinib, sorafenib, and temsirolimus-have been approved for use in the United States recently. Current research is aimed at developing new drugs and combining available drugs to improve upon the responses and survival seen with approved single agents.

引用

页码：687 / 701

页数：15

共 94 条

[1]

Amato RJ, 2007, J CLIN ONCOL, V25

[2] Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum [J].

Argani, Pedram ;

Olgac, Semra ;

Tickoo, Satish K. ;

Goldfischer, Michael ;

Moch, Holger ;

Chan, David Y. ;

Eble, John N. ;

Bonsib, Stephen M. ;

Jimeno, Mireya ;

Lloreta, Josep ;

Billis, Athanase ;

Hicks, Jessica ;

De Marzo, Angelo M. ;

Reuter, Victor E. ;

Ladanyi, Marc .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (08) :1149-1160

[3] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[4] When translation meets transformation: the mTOR story [J].

Averous, J. ;

Proud, C. G. .

ONCOGENE, 2006, 25 (48) :6423-6435

[5]

Azad NS, 2007, J CLIN ONCOL, V25

[6] Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe [J].

Barkholt, L. ;

Bregni, M. ;

Remberger, M. ;

Blaise, D. ;

Peccatori, J. ;

Massenkeil, G. ;

Pedrazzoli, P. ;

Zambelli, A. ;

Bay, J. -O. ;

Francois, S. ;

Martino, R. ;

Bengala, C. ;

Brune, M. ;

Lenhoff, S. ;

Porcellini, A. ;

Falda, M. ;

Siena, S. ;

Demirer, T. ;

Niederwieser, D. ;

Ringden, O. .

ANNALS OF ONCOLOGY, 2006, 17 (07) :1134-1140

[7] A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma [J].

Bleumer, I ;

Oosterwijk, E ;

Oosterwijk-Wakka, JC ;

Völler, MCW ;

Melchior, S ;

Warnaar, SO ;

Mala, C ;

Beck, J ;

Mulders, PFA .

JOURNAL OF UROLOGY, 2006, 175 (01) :57-62

[8]

BULKOWSKI RM, 2007, J CLIN ONCOL, V25, P4536

[9] Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].

Childs, R ;

Chernoff, A ;

Contentin, N ;

Bahceci, E ;

Schrump, D ;

Leitman, S ;

Read, EJ ;

Tisdale, J ;

Dunbar, C ;

Linehan, WM ;

Young, NS ;

Barrett, AJ ;

Clave, E ;

Epperson, D ;

Mayo, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758

[10]

Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223

← 1 2 3 4 5 6 7 8 9 10 →